Foa, Robin
 Distribuzione geografica
Continente #
NA - Nord America 1.875
AS - Asia 1.249
EU - Europa 856
SA - Sud America 278
AF - Africa 32
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 3
Totale 4.298
Nazione #
US - Stati Uniti d'America 1.836
SG - Singapore 571
CN - Cina 285
BR - Brasile 231
SE - Svezia 223
IT - Italia 157
VN - Vietnam 113
DE - Germania 105
FR - Francia 99
IN - India 79
IE - Irlanda 66
PL - Polonia 62
GB - Regno Unito 42
ID - Indonesia 39
JP - Giappone 33
AR - Argentina 25
RU - Federazione Russa 25
HK - Hong Kong 24
FI - Finlandia 21
BD - Bangladesh 16
MX - Messico 15
CA - Canada 14
TR - Turchia 14
AT - Austria 13
KR - Corea 13
UA - Ucraina 13
IQ - Iraq 9
ZA - Sudafrica 9
MA - Marocco 6
PK - Pakistan 6
AU - Australia 5
CH - Svizzera 5
EG - Egitto 5
JO - Giordania 5
KZ - Kazakistan 5
LT - Lituania 5
SA - Arabia Saudita 5
PY - Paraguay 4
UZ - Uzbekistan 4
VE - Venezuela 4
AZ - Azerbaigian 3
DZ - Algeria 3
IL - Israele 3
NL - Olanda 3
NP - Nepal 3
PE - Perù 3
UY - Uruguay 3
BE - Belgio 2
BO - Bolivia 2
CI - Costa d'Avorio 2
CL - Cile 2
CO - Colombia 2
CZ - Repubblica Ceca 2
EC - Ecuador 2
ES - Italia 2
ET - Etiopia 2
IR - Iran 2
MY - Malesia 2
RO - Romania 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
AL - Albania 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
CR - Costa Rica 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
DM - Dominica 1
DO - Repubblica Dominicana 1
EU - Europa 1
GA - Gabon 1
GE - Georgia 1
GR - Grecia 1
JM - Giamaica 1
KE - Kenya 1
KW - Kuwait 1
LB - Libano 1
LI - Liechtenstein 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MM - Myanmar 1
MN - Mongolia 1
NG - Nigeria 1
NI - Nicaragua 1
OM - Oman 1
PA - Panama 1
PH - Filippine 1
PS - Palestinian Territory 1
PT - Portogallo 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TM - Turkmenistan 1
TN - Tunisia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 4.298
Città #
Singapore 308
Chandler 186
San Jose 136
Ashburn 131
New York 69
Beijing 58
Dublin 58
Warsaw 56
Dallas 50
Dearborn 44
Lauterbourg 43
Los Angeles 42
Hyderabad 41
Florence 38
Hefei 37
Ho Chi Minh City 37
Jakarta 37
Frankfurt am Main 34
Tokyo 32
Hanoi 31
Princeton 27
San Mateo 24
Hong Kong 23
São Paulo 23
Wilmington 23
Milan 21
Redwood City 21
Nanjing 18
Albany 16
Minneapolis 16
Chicago 15
Helsinki 15
Boston 14
Nanchang 14
Houston 13
Moscow 13
Pune 13
Seoul 13
Council Bluffs 12
Kunming 12
Düsseldorf 11
Munich 10
Norwalk 10
London 9
Marseille 9
Belo Horizonte 8
Izmir 8
Nuremberg 8
Seattle 8
Atlanta 7
Cattolica 7
Fairfield 7
Jacksonville 7
Kent 7
Orem 7
The Dalles 7
Tianjin 7
Garden City 6
Johannesburg 6
Paris 6
Rio de Janeiro 6
Rome 6
Santa Clara 6
Amman 5
Bologna 5
Brooklyn 5
Buenos Aires 5
Changsha 5
Dhaka 5
Wroclaw 5
Baghdad 4
Benalla 4
Brasília 4
Curitiba 4
Elk Grove Village 4
Engelhard 4
Genoa 4
Goiânia 4
Guangzhou 4
Haiphong 4
Lahore 4
Manchester 4
Poplar 4
Portsmouth 4
Querétaro 4
Shenyang 4
Tashkent 4
Toronto 4
Vicopisano 4
Vienna 4
Washington 4
Ankara 3
Araraquara 3
Baku 3
Bắc Giang 3
Cairo 3
Catanduva 3
Cleveland 3
Columbus 3
Falls Church 3
Totale 2.133
Nome #
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation 659
Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia 182
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 156
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 151
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: Correlation with biologically-based risk stratification 141
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors. A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (Gitmo) 129
Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib 125
Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma 122
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 122
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study 116
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 114
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments. 110
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study 110
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group 108
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study 107
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study 102
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 102
Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia 99
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “Real-World” study 98
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL 97
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report 96
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 93
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia 91
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus 91
Anti-HLA donor-specific antibodies in allogeneic stem cell transplantation: management and desensitization protocol 90
Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: A Campus CLL report 90
BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study 87
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia 85
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. 83
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study 82
Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab 82
A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia 81
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model 80
Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment 73
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study 72
Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases 70
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 57
Totale 4.353
Categoria #
all - tutte 18.016
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.016


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202111 0 0 0 0 0 0 0 0 0 0 7 4
2021/2022279 8 3 47 35 36 6 2 31 9 9 60 33
2022/2023489 64 73 32 58 37 67 14 31 65 7 31 10
2023/2024866 20 78 29 540 20 97 8 10 2 10 15 37
2024/2025724 24 16 47 23 49 35 22 32 93 134 157 92
2025/20261.580 268 55 142 207 270 97 252 74 96 107 12 0
Totale 4.353